Hemlibra Doesn't Replace Factor VIII. It Does Factor VIII's Job.

The bridge

Blood clotting is a cascade - a chain of proteins activating each other in sequence until a clot forms. Factor VIII is one link in that chain. Its job is to bring two other proteins - Factor IXa and Factor X - together on a cell surface so Factor X can be activated. Factor VIII is the bridge between them.

Hemophilia A patients have a deficiency or absence of Factor VIII. Without the bridge, Factor IXa and Factor X don't come together efficiently, the cascade stalls, and blood doesn't clot properly. Severe hemophilia A (less than 1% of normal Factor VIII activity) causes spontaneous bleeding into joints, muscles, and organs.

What treatment looked like

For decades, the treatment for hemophilia A was Factor VIII replacement - intravenous infusions of recombinant or plasma-derived Factor VIII to temporarily restore clotting function. Standard half-life products required infusions roughly three times per week. Extended half-life products reduced this to one or two times per week, but still required IV access.

Repeated IV infusions damage veins over time. Patients describe scarring, difficulty finding a usable vein, swelling at injection sites. Some require surgically implanted ports, which carry infection risk. Children need more frequent infusions than adults because they clear Factor VIII faster.

And for about 30% of patients with severe hemophilia A, replacement therapy stops working entirely. Their immune system develops inhibitors - antibodies that neutralize Factor VIII. The treatment they depend on becomes useless. Before Hemlibra, these patients had limited options: bypassing agents (FEIBA, NovoSeven) that work around the missing factor but are less effective and more expensive, or immune tolerance induction - months or years of high-dose Factor VIII to desensitize the immune system, which doesn't always succeed.

What Hemlibra does

Roche's Hemlibra (emicizumab) is a bispecific antibody. One arm binds Factor IXa. The other arm binds Factor X. It physically holds them together in the correct orientation on a phospholipid surface, mimicking the bridging function that Factor VIII normally performs.

Hemlibra is not Factor VIII. It doesn't contain Factor VIII. It doesn't look like Factor VIII to the immune system. This is why it works in patients with inhibitors - the antibodies that neutralize Factor VIII don't recognize emicizumab, because it's a completely different molecule that happens to do the same job.

It's given by subcutaneous injection - under the skin, not into a vein. Dosing is once weekly, every two weeks, or every four weeks, depending on the regimen. No IV access. No vein damage. No ports.

The HAVEN trials

Roche tested Hemlibra across four pivotal trials covering the major hemophilia A populations.

HAVEN 1 was the breakthrough. Patients with inhibitors - the population with the fewest options - saw treated bleeds drop from 23.3 per year with no prophylaxis to 2.9 per year with Hemlibra. 63% had zero bleeding events during the study. The FDA approved Hemlibra in November 2017, initially for hemophilia A patients with inhibitors.

HAVEN 3 then showed that Hemlibra was also superior to Factor VIII prophylaxis in patients without inhibitors - a 68% reduction in bleeding rate compared to their prior Factor VIII regimen. The label expanded to all hemophilia A patients regardless of inhibitor status.

Want the next brief? Subscribe - free, every two weeks.

The numbers

Hemlibra is now the most prescribed hemophilia A therapy, overtaking Takeda's Advate (recombinant Factor VIII). Revenue has grown every year since launch: $3.3 billion in 2021, $4.0 billion in 2022, $4.6 billion in 2023, $4.9 billion in 2024, reaching $5.6 billion annualized in 2025. It is Roche's second-largest product.

The global hemophilia A treatment market was valued at approximately $10.5 billion in 2024. Factor replacement therapy still holds about 61% market share, but that share is declining as non-factor therapies grow. Hemlibra alone accounts for roughly half of the hemophilia A market by revenue.

Four modalities, one disease

Hemophilia A is now treated by five distinct modalities - each using a different scientific approach to solve the same clotting problem.

Factor VIII replacement directly provides the missing protein. Sanofi's Altuviiio, an extended half-life version that maintains factor levels for about seven days, grew from $171 million in 2023 to $702 million in 2024. Both still require intravenous infusion.

Sanofi's fitusiran (Qfitlia), approved by the FDA in March 2025, takes a different approach entirely. It's an siRNA - a small interfering RNA that silences the gene for antithrombin, a natural anticoagulant. By removing the brake on clotting, it restores hemostatic balance without replacing or mimicking Factor VIII. It works in both hemophilia A and hemophilia B, with or without inhibitors.

Pfizer's Hympavzi (marstacimab), approved in October 2024, blocks tissue factor pathway inhibitor (TFPI) - another natural anticoagulant. Same concept as fitusiran (remove a brake) but using an antibody instead of siRNA.

BioMarin's Roctavian, the first FDA-approved gene therapy for hemophilia A, used an AAV5 vector to deliver a functional Factor VIII gene in a one-time infusion. It was priced at $2.9 million. BioMarin voluntarily withdrew it from the market in late 2025 after generating only $26 million in revenue in 2024 - the same commercial challenges seen across the gene therapy field.

Five approaches to the same disease. Factor replacement provides the missing protein. Extended half-life FVIII makes it last longer. Hemlibra mimics its function with a bispecific bridge. Fitusiran and Hympavzi remove natural brakes on clotting. Gene therapy attempted to fix the underlying gene. Each reflects a different way of thinking about the same problem.

Hemlibra's two arms bridge two proteins. Other bispecific antibodies use their two arms differently - T-cell engagers force an immune cell and a cancer cell together, and Vabysmo blocks two pathways simultaneously in the eye. Same concept, three different jobs.